Introduction: Medication-related osteonecrosis of the jaws (MRONJ) is generally described as rare; therefore, firm incidence data are challenging to ascertain.
Aim: Using two sites in Northwest England, ascertain the number of referrals to oral and maxillofacial surgery involving: Suspected MRONJ. Patients at risk of MRONJ requiring a dentoalveolar procedure.
Method: All sequential referrals over a 2-year period were analysed. The referrals were categorised into 'type' of referral (stage 1). Any referral for MRONJ, or patient at risk, was then further examined (stage 2).
Results: A total of 2150 referrals were screened. The most common referral reasons were temporomandibular joint issues and hard tissue conditions. The proportion of referrals for suspected MRONJ was similar for both sites: 3.7% (site 1) and 3.4% (site 2). At site 1, 1.6% of all referrals were at risk of MRONJ referred for treatment. In site 2, 3.8% of all referrals were in this category.
Conclusion: Despite limitations, the finding that patients with or at risk of MRONJ potentially equates to 7% of all referrals represents a substantial proportion of OMFS practice. Therefore, there are clear benefits of collecting accurate data prospectively to understand the scale of this condition and its impact on services.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863808 | PMC |
| http://dx.doi.org/10.1038/s41405-022-00097-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Medication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMS.
J Bone Oncol
February 2025
Unit of Oral Medicine and Dentistry for Frail Patients, Department of Rehabilitation, Fragility, and Continuity of Care, Regional Center for Research and Care of MRONJ, University Hospital Palermo, Palermo, PA, Italy.
Background: Low-doses of bone modifying agents (LD-BMAs) compared to those used to treat bone metastases are used in breast or prostate cancer patients on adjuvant endocrine therapy to prevent Cancer Treatment Induced Bone Loss (CTIBL). Their use is associated with an increased risk of developing Medication-Related Osteonecrosis of the Jaw (MRONJ). However, there is not clarity about strategies aimed to minimize the MRONJ risk in cancer patients at different conditions as low- vs high-doses of BMA.
View Article and Find Full Text PDFPrediction of Medication-Related Osteonecrosis of the Jaw in Patients Receiving Antiresorptive Therapy Using Machine Learning Models.
J Oral Maxillofac Surg
December 2024
Assistant Professor, Research and Data Development, The Securities and Exchange Commission, Bangkok, Thailand.
Background: Medication-related osteonecrosis of the jaw (MRONJ) is a serious complication associated with the use of antiresorptive agents, impacting patient quality of life and treatment outcomes. Predictive modeling may aid in a better understanding of MRONJ development.
Purpose: The study aimed to evaluate machine learning (ML)-based models for predicting MRONJ in patients receiving antiresorptive therapy.
Prevention of medication-related osteonecrosis of the jaw: institutional insights from a retrospective study.
Aust Dent J
December 2024
The School of Dentistry, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Background: Medication-related osteonecrosis of the jaw (MRONJ) is a serious, debilitating condition of the jaw bones. Dental extraction is the most significant independent risk factor for MRONJ. This interim study aimed to evaluate the demographics, medical data and outcomes of patients at risk for MRONJ who underwent dental extractions in a dedicated MRONJ clinic following a risk reduction protocol at a large public dental clinic in New South Wales Health.
View Article and Find Full Text PDFObjectives: This study aimed to investigate periodontal stability and treatment needs in patients under antiresorptive therapy (ART) during supportive periodontal care (SPC), with a focus on medication-related osteonecrosis of the jaw (MRONJ) risk and reasons for tooth loss.
Method And Materials: In this retrospective case-control study, records of 100 stage III/IV SPC patients (50 ART-exposed, 50 unexposed) were analyzed for probing pocket depth (PPD), clinical attachment level (CAL), bleeding on probing (BOP), history of periodontal surgery, tooth loss and MRONJ risk over a period of up to 15 years after active periodontal therapy.
Results: Baseline patient characteristics were similar between ART-exposed and unexposed patients.
Chinese expert consensus on the diagnosis and clinical management of medication-related osteonecrosis of the jaw.
J Bone Oncol
December 2024
Department of Oral Maxillofacial & Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, National Clinical Research Center for Oral Disease, National Clinical Research Center for Oral Diseases, Shanghai, China.
Article Synopsis
- Medication-related osteonecrosis of the jaw (MRONJ) results from systemic disease treatments, with current diagnosis and treatment methods being largely empirical and lacking consensus in China.
- An expert panel from 11 medical institutions conducted a literature review to establish clearer definitions, risk factors, and treatment strategies for MRONJ.
- They recommend that MRONJ diagnosis rely on medication history and clinical signs, advocate surgical options for symptomatic cases, and emphasize a multidisciplinary approach for better treatment outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!